Vanguard Rapid Resp: First Vaccines to Provide 1-Year Immunity from 3 CIRDs

Vanguard Rapid Resp, marketed by Zoetis, is now the first and only family of intranasal vaccines demonstrated to provide 1 year of protection against 3 canine infectious respiratory diseases (CIRDs): Bordetella bronchiseptica (Bb), canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPiV) fractions.

Bb can cause infectious bronchitis, CAV-2 can cause infectious tracheobronchitis, and CPiV can cause both. While each CIRD can be generated by different pathogens, the clinical signs are identical in most instances—making treatment identification difficult.

“The demonstration of a 1-year duration of immunity for all 3 antigens in Vanguard Rapid Resp represents an important step in the protection of dogs from CIRD,” said Stephan Carey, DVM, PhD, DACVIM, assistant professor of small animal clinical sciences at Michigan State University College of Veterinary Medicine. “This new DOI confirms the efficacy of a single product that provides both rapid and durable protection against these important antigens in the CIRD complex.”

Vanguard Rapid Resp is available in 3 different antigenic combinations: Bb + CPiV + CAV-2, Bb + CPiV, and Bb only. All combinations can be administered with either a syringe or a syringe-free applicator, and should only be administered to healthy dogs 8 weeks of age or older.

“This extended DOI is essential in reducing morbidity and mortality from infectious respiratory disease among dogs in social or commingled environments such as boarding facilities and shelters,” Dr. Carey said.

Since co-infections occur often when dogs contract CIRDs, which leads to more severe symptoms, the addition of this multivalent immunization protocol can help veterinarians prevent the preventable.

More information about Vanguard Rapid Resp is available on the Zoetis website.